YAG
RNAZ icon

Yorkville Advisors Global’s TransCode Therapeutics RNAZ Stock Holding History

Yorkville Advisors Global’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
+19,639
New +$134K 0.14% 29

Other funds holding RNAZ

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Yorkville Advisors Global's RNAZ Position: Q2 2026 in Review

Yorkville Advisors Global opened a new position in TransCode Therapeutics (RNAZ) in Q2 2026: 19,639 shares worth $122K. The stake represents 0.14% of the portfolio and ranks #29 among its holdings.

7 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

  • Yorkville Advisors Global held 19,639 shares of TransCode Therapeutics worth $122K as of Q2 2026.
  • TransCode Therapeutics was a new Yorkville Advisors Global position in Q2 2026.
  • TransCode Therapeutics made up 0.14% of Yorkville Advisors Global's portfolio in Q2 2026, its #29 holding.
  • 7 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Yorkville Advisors Global's 13F filing for Q2 2026, filed 6 Aug 2026.